UNION CITY, Calif., March 6, 2009 (GLOBE NEWSWIRE) -- Questcor Pharmaceuticals, Inc. (Nasdaq:QCOR) announced today that NASDAQ has approved its application to transfer from the NASDAQ Capital Market. Effective today, March 6, the Company's common stock will trade on The NASDAQ Global Market. The stock symbol QCOR remains the same.
"We believe that this move to The NASDAQ Global Market will provide Questcor with greater visibility to a broader range of potential investors," said Don M. Bailey, President and CEO of Questcor. "The listing qualifications for the NASDAQ Global Market are rigorous and we are very pleased to have met the standards of a NASDAQ Global Market company."
About Questcor
Questcor Pharmaceuticals, Inc. is a pharmaceutical company that markets two commercial products, H.P. Acthar(r) Gel ("Acthar") and Doral(r). Acthar (repository corticotropin injection) is an injectable drug that is approved for the treatment of certain disorders with an inflammatory component, including the treatment of exacerbations associated with multiple sclerosis ("MS") and to induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythamatosus. In addition, Acthar is not indicated for, but is used in treating patients with infantile spasms ("IS"), a rare form of refractory childhood epilepsy, and opsoclonus myoclonus syndrome, a rare autoimmune-related childhood neurological disorder. Doral is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. For more information, please visit www.questcor.com.